Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

Shintaro Hirata, Wanying Li, Satoshi Kubo, Shunsuke Fukuyo, Yasushi Mizuno, Kentaro Hanami, Norifumi Sawamukai, Kunihiro Yamaoka, Kazuyoshi Saito, Nadine A. Defranoux, Yoshiya Tanaka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p 

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2016 Mar 22

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Joints
Biomarkers
Therapeutics
Joint Diseases
Nonparametric Statistics
Area Under Curve

Keywords

  • Biomarkers
  • MBDA score
  • Radiographic progression
  • Rheumatoid arthritis
  • TNF inhibitor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. / Hirata, Shintaro; Li, Wanying; Kubo, Satoshi; Fukuyo, Shunsuke; Mizuno, Yasushi; Hanami, Kentaro; Sawamukai, Norifumi; Yamaoka, Kunihiro; Saito, Kazuyoshi; Defranoux, Nadine A.; Tanaka, Yoshiya.

In: Modern Rheumatology, 22.03.2016, p. 1-7.

Research output: Contribution to journalArticle

Hirata, Shintaro ; Li, Wanying ; Kubo, Satoshi ; Fukuyo, Shunsuke ; Mizuno, Yasushi ; Hanami, Kentaro ; Sawamukai, Norifumi ; Yamaoka, Kunihiro ; Saito, Kazuyoshi ; Defranoux, Nadine A. ; Tanaka, Yoshiya. / Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. In: Modern Rheumatology. 2016 ; pp. 1-7.
@article{b10321adea8f4d7e845657cdee714ad3,
title = "Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice",
abstract = "Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34{\%} of patients had ΔmTSS >0.5 and 12{\%} had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p ",
keywords = "Biomarkers, MBDA score, Radiographic progression, Rheumatoid arthritis, TNF inhibitor",
author = "Shintaro Hirata and Wanying Li and Satoshi Kubo and Shunsuke Fukuyo and Yasushi Mizuno and Kentaro Hanami and Norifumi Sawamukai and Kunihiro Yamaoka and Kazuyoshi Saito and Defranoux, {Nadine A.} and Yoshiya Tanaka",
year = "2016",
month = "3",
day = "22",
doi = "10.3109/14397595.2016.1153449",
language = "English",
pages = "1--7",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

AU - Hirata, Shintaro

AU - Li, Wanying

AU - Kubo, Satoshi

AU - Fukuyo, Shunsuke

AU - Mizuno, Yasushi

AU - Hanami, Kentaro

AU - Sawamukai, Norifumi

AU - Yamaoka, Kunihiro

AU - Saito, Kazuyoshi

AU - Defranoux, Nadine A.

AU - Tanaka, Yoshiya

PY - 2016/3/22

Y1 - 2016/3/22

N2 - Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p 

AB - Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p 

KW - Biomarkers

KW - MBDA score

KW - Radiographic progression

KW - Rheumatoid arthritis

KW - TNF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84961863008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961863008&partnerID=8YFLogxK

U2 - 10.3109/14397595.2016.1153449

DO - 10.3109/14397595.2016.1153449

M3 - Article

SP - 1

EP - 7

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -